Researchers have found in a new study that asymptomatic kidney stones are linked to a faster decline in kidney function in patients with autosomal dominant polycystic kidney disease (ADPKD).

Regulus Therapeutics (RGLS) stock soars after positive Phase 1b trial data for the company's lead asset, farabursen against a ...

A man who was given a life-saving kidney by his wife has told of how he will "never be able to repay her" for donating the ...

In March 2025, Shandong Suncadia Medicine Co., Ltd. conducted a phase II Clinical Study of Efficacy and Safety of HRS-1780 ...

One said: "I have street cats, from a rescue. Almost no need for a vet. Okay, as they got older. But, they got old/ getting ...

A New Port Richey father is battling kidney disease as he searches for a donor. NEW PORT RICHEY, Fla. - March marks national kidney month; a time to raise awareness about kidney diseases, like ...

The following is a summary of “Long-term effect of tolvaptan treatment on kidney function and volume in patients with ADPKD,” ...

Clinicians should monitor patients with stones, even if they are asymptomatic, to slow kidney function decline, investigators suggest. Even asymptomatic kidney stones may spur kidney function decline ...

Regulus (RGLS) announced positive topline results from all patients in the fourth cohort in its Phase 1b MAD study of farabursen for the ...

As previously reported, Wells Fargo analyst Yanan Zhu upgraded Regulus (RGLS) to Overweight from Equal Weight with a price target of $6, up ...

A man who was given a life-saving kidney by his wife has told of how he will "never be able to repay her" for donating the ...

Investing.com -- Shares of Regulus Therapeutics (NASDAQ: RGLS) soared 23.3% today following the announcement of successful results from its Phase 1b multiple ascending dose (MAD) clinical trial of ...